Pivotal NAVAL-1 Trial Achieves Efficacy Threshold for Expansion in R/R EBV+ PTCL
“Initial data from the PTCL cohort in NAVAL-1 show a strong signal of efficacy that is in-line with our promising Phase 1b/2 data and sufficient to advance to Stage 2. We now look forward to completing enrollment in Stage 1 and are taking steps to further accelerate enrollment through Stage 2,” said Mark Rothera, President and Chief Executive Officer of Viracta. “Given the lack of effective therapies available for patients with PTCL, today’s announcement represents an important step towards addressing a pressing unmet medical need. The advancement of the first cohort into Stage 2 establishes PTCL as the leading indication for the NAVAL-1 clinical trial and provides added momentum to our global clinical program.”
Share:
More News
“Initiation of the TEADCO Phase 1b/2 basket trial is another important milestone for the ODM-212 clinical development program and reflects our commitment to patients with difficult-to-treat cancers,” said Professor Outi Vaarala, Executive Vice President, Research & Development at Orion. “Together with the ongoing TEADES study, TEADCO highlights the versatility of
“In this study, tovecimig showed an impressive overall response rate which translated into a clinically meaningful and highly statistically significant improvement in PFS for patients with previously treated BTC. The remarkable 56% reduction in the risk of disease progression is unprecedented in this patient population without an actionable mutation in
“We are encouraged to see taletrectinib (IBTROZI) added to the NCCN Guidelines® for CNS Cancers given its demonstrated high rates of intracranial response that are durable in ROS1+ NSCLC patients with brain metastases,” said David Hung, M.D., Founder, President and Chief Executive Officer of Nuvation Bio. “Given the prevalence of
Daniel Getts, Ph.D., CEO of CREATE, added “MT-304 is proof of what our platform can do, and what our team can execute. Our mRNA-LNP leadership enables us to move from concept to clinic with remarkable speed. Just last weekend at AACR, we presented compelling preclinical data across our in vivo